Stockreport

Taysha Gene Therapies Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Taysha Gene Therapies, Inc.  (TSHA) 
PDF High dose TSHA-102 was generally well tolerated with no SAEs or DLTs in two adolescent/adult patients and one pediatric patient as of data cutoff; IDMC approved continue [Read more]